Adults who completed 72 weeks of injectable tirzepatide or semaglutide in SURMOUNT-5.
Foundayo
Phase
Phase 3b
Follow-up
52 weeks
Randomised
376
Sponsor
Eli Lilly
Publication
Nature Medicine · 2026
Double-blind, placebo-controlled. Participants switched to orforglipron or placebo, with no arm continuing injections. From week 24, placebo participants who regained at least half their prior weight loss could receive rescue treatment. The primary result uses a modified treatment-regimen analysis and keeps the two prior-treatment cohorts separate. The study randomised 376 people in total.
Estimated share of earlier weight loss maintained at week 52 among participants who had reached a weight plateau
0%100%
Orforglipron after tirzepatide74.7%
Placebo after tirzepatide49.2%
Orforglipron after semaglutide79.3%
Placebo after semaglutide37.6%
Estimated share of earlier weight loss maintained at week 52 among participants who had reached a weight plateau
Trial arm
Result
Orforglipron after tirzepatide
74.7%
Placebo after tirzepatide
49.2%
Orforglipron after semaglutide
79.3%
Placebo after semaglutide
37.6%
Safety. Gastrointestinal events were the most common adverse events.
DarDoc's pricing covers a range of services including lab tests, home healthcare visits, IV therapy, wellness programmes, weight management, supplements, and other wellness services, provided through DarDoc and its licensed partners across the UAE. Pricing may vary by service type, emirate, provider, and time of booking. Subscription plans are billed on a recurring basis and grant access to a defined set of services at a bundled rate; pay-per-service options are charged at the time of booking confirmation. A full itemisation of all fees applicable to your selected service or plan is available on request at any time. Please note that some services, add-ons, or follow-up consultations may require additional payment not included in your selected plan or membership tier.